Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 1
2006 1
2009 1
2017 1
2018 1
2019 1
2020 2
2021 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial.
Yang H, Xu L, Guan S, Hao X, Ge Z, Tong F, Cao Y, Liu P, Zhou B, Cheng L, Liu M, Liu H, Xie F, Wang S, Peng Y, Wang C, Wang S. Yang H, et al. Among authors: cao y. BMC Cancer. 2022 Dec 28;22(1):1357. doi: 10.1186/s12885-022-10439-0. BMC Cancer. 2022. PMID: 36577958 Free PMC article. Clinical Trial.
Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?
Yang H, Zhou L, Wang S, Cao Y, Tong F, Liu P, Zhou B, Cheng L, Liu M, Liu H, Xie F, Guo J, Wang S, Peng Y. Yang H, et al. Among authors: cao y. Medicine (Baltimore). 2018 Oct;97(40):e12690. doi: 10.1097/MD.0000000000012690. Medicine (Baltimore). 2018. PMID: 30290661 Free PMC article.
14 results